TAK-243 治疗复发或难治性急性髓性白血病或难治性骨髓增生异常综合征或慢性粒单核细胞白血病患者
MLN7243 (TAK-243) 治疗复发/难治性急性髓性白血病或骨髓增生异常综合征/低甲基化药物难治性慢性粒单核细胞白血病的 1 期研究
This phase I trial studies the side effects and best dose of TAK-243 in treating patients with acute myeloid leukemia or myelodysplastic syndromes with increased blasts that has come back (relapsed) or that is not responding to treatment (refractory). TAK-243 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
研究概览
地位
条件
详细说明
PRIMARY OBJECTIVE:
I. To establish the recommended phase 2 dose (RP2D) of UAE inhibitor TAK-243 (TAK-243) administered intravenously in a twice-weekly schedule in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
SECONDARY OBJECTIVES:
I. To assess the maximum tolerated dose (MTD) evaluated on the first cycle (Day 1 to 21) of TAK-243, its safety profile, and dose limiting toxicities (DLT).
II. To investigate preliminary anti-leukemic activity of TAK-243 monotherapy in patients with AML or MDS.
III. To describe the pharmacokinetic (PK) profile of TAK-243. IV. To describe the pharmacodynamic (PD) effects of TAK-243.
EXPLORATORY OBJECTIVE:
I. To investigate associations between clinical responses and molecular/cytogenetic abnormalities in the leukemia cells or to the PK profile or PD effects of TAK-243.
OUTLINE: This is a dose-escalation study.
Patients receive TAK-243 intravenously (IV) over 30 minutes on days 1, 4, 8, and 11 of each cycle. Cycles repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients undergo urine sample collection, bone marrow aspiration and bone marrow biopsy, multigated acquisition scan (MUGA) and echocardiogram (ECHO) during screening and on study, and blood sample collection throughout the trial.
After completion of study treatment, patients are followed up at 30 days.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G 2M9
- University Health Network-Princess Margaret Hospital
-
-
-
-
Florida
-
Tampa、Florida、美国、33612
- Moffitt Cancer Center
-
-
Illinois
-
Chicago、Illinois、美国、60611
- Northwestern University
-
-
Ohio
-
Columbus、Ohio、美国、43210
- Ohio State University Comprehensive Cancer Center
-
-
Virginia
-
Richmond、Virginia、美国、23298
- VCU Massey Comprehensive Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Diagnosis of AML or MDS with increased blasts (MDS-IB) assessed by local laboratory review according to the 2022 World Health Organization (WHO) criteria for myeloid neoplasms. Both patients with MDS-IB1 (5-9% bone marrow blasts) and MDS-IB2 (10-19% bone marrow blasts) are eligible.
-
Patients must have relapsed or refractory disease after receiving at least one prior line of therapy
-
AML-specific inclusion criteria: Patients with relapsed or refractory AML with >= 5% bone marrow blasts after receiving at least two courses of intensive induction chemotherapy (including, but not limited to, 7+3 regimen, fludarabine, cytarabine, idarubicin and filgrastim [FLAG-Ida] and mitoxantrone, etoposide, and cytarabine [MEC]) or 2 cycles of venetoclax-based lower intensity regimen (azacitidine plus venetoclax or low-dose cytarabine plus venetoclax), and without any other approved therapies available that would be more appropriate in the investigator's judgment. Patients who have received only one course of intensive induction chemotherapy but are not eligible for a second course because of decreased performance status or clear disease progression may be eligible for participation after discussion with the study principal investigator (PI). Patients with concomitant extramedullary disease relapse are eligible to participate, but not patients with isolated extramedullary relapse without bone marrow disease.
-
MDS-specific inclusion criteria: Patients with relapsed or refractory MDS-IB with >= 5% bone marrow blasts after at least 4 cycles of hypomethylating agent (HMA)-based therapy or at least two courses of intensive induction chemotherapy and meet criteria for stable disease (SD), progressive disease (PD) or disease relapse according to the International Working Group 2023 response criteria for higher-risk MDS. Patients must not have access to any other approved therapies that would be more appropriate in the investigator's judgment. Patients who have received less than 4 cycles of HMA-based therapy may be eligible to participate after discussion with the study PI if there is clear evidence of progression or intolerance to HMA-based therapy that precludes its continuation.
-
Patients must have recovered from the effects of any prior systemic therapy, radiotherapy or surgery:
- Patients should not have received other investigational therapy within 2 weeks.
- Patients should not have received standard chemotherapy within 1 week of administration of study drug; hydroxyurea administration (for leukocyte count control) is permitted.
-
Age >=18 years. Because no dosing or adverse event data are currently available on the use of TAK-243 in patients < 18 years of age, children are excluded from this study.
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 50%).
-
Serum bilirubin =< 1.5 × institutional upper limit of normal (ULN).
- Patients with a known history of Gilbert's syndrome may enroll.
-
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 × institutional ULN.
-
Serum creatinine < 176 mcmol/L (2 mg/dL) OR
-
Creatinine clearance ≥ 60 mL/min based on the Cockcroft-Gault equation.
-
Documented normal cardiac function (>= 50%) by echocardiogram or multi-gated acquisition (MUGA) scan.
-
HIV-infected patients on effective anti-retroviral therapy with undetectable viral load withing 6 months are eligible for this trial.
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, HBV viral load must be undetectable on suppressive therapy if indicated.
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
-
The effects of TAK-243 on the developing human fetus are unknown and ubiquitin-activating enzyme inhibitors are known to be teratogenic. For this reason, female patients must be:
- Postmenopausal (age-related amenorrhea >= 12 consecutive months or follicle-stimulating hormone > 40 mIU/mL), for at least 1 year before the screening visit, OR
- Surgically sterile (i.e., who had undergone hysterectomy or bilateral oophorectomy), OR
If they are of childbearing potential:
-
Agree to practice 1 highly effective method and 1 additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug (female and male condoms should not be used together), OR
-
Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.) Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
- Male patients, even if surgically sterilized (i.e., status post-vasectomy), who:
-
Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug (female and male condoms should not be used together), OR
-
Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods for the female partner] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.)
- Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.
- Patients should have a minimum life expectancy of 1 month.
Exclusion Criteria:
-
Patients with acute promyelocytic leukemia (APL) or AML with t(15;17)(q22;q12) - PML::RARA).
-
Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1), except anemia, neutropenia or thrombocytopenia of any grade and grade 2 peripheral neuropathy.
-
Presence of any other malignancy requiring active therapy.
-
Patients who are receiving any other investigational agents.
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to TAK-243.
-
Concomitant treatment with organic anion transport protein (OATP) and BCRP inhibitors or strong inducers/inhibitors of cytochrome P450 (CYP)3A4/5. Treatment with these agents must be discontinued at least 14 days prior to TAK-243 dosing. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product.
-
Presence of an active uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, or septicemia.
-
Presence of active graft-versus-host disease (GVHD) or continued treatment with systemic immunosuppressive agents following allogeneic hematopoietic stem cell transplantation (HSCT).
-
Presence of any co-morbid condition that, in the opinion of the investigator, might compromise the patient's safety, might interfere with participation in the trial or might interfere with the interpretation of trial results.
-
Pregnant and lactating/breast-feeding women are excluded from this study because TAK-243 is a UAE-inhibiting agent with the potential for teratogenic or abortifacient effects and there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with TAK-243. Females of child-bearing potential must have a negative serum pregnancy test within 7 days before enrollment and should not be lactating/breast-feeding. Breastfeeding should be discontinued if the mother is treated with TAK-243.
-
Major surgery within 14 days before the first dose of any study drug or a scheduled surgery during study period.
-
Patients with uncontrolled coagulopathy or bleeding disorder.
-
Patients with known hepatic cirrhosis.
-
Patients with known active cardiopulmonary disease defined as:
- Unstable angina withing 3 months prior to first dose of TAK-243;
- Myocardial infarction (MI) within 6 months prior to first dose of TAK-243 (patients who had MI and/or coronary revascularization more than 6 months before screening and who are without cardiac symptoms may enroll);
- Congestive heart failure (New York Heart Association [NYHA] Class III or IV;
- Cardiomyopathy with left ventricular ejection fraction (LVEF) < 50%;
- Symptomatic pulmonary hypertension.
-
Presence of active central nervous system (CNS) involvement (patients with prior CNS leukemia who have negative CNS cytology and who receive periodic prophylactic intrathecal chemotherapy are eligible).
-
Patients with clinically significant arrhythmia:
- History of ventricular fibrillation or torsade de pointes at any time,
- Episode of grade >= 3 atrial fibrillation or flutter in the last 3 months, defined as symptomatic episode, requiring urgent intervention (cardioversion, pacemaker or ablation) or with life-threatening consequences.
-
Uncontrolled high blood pressure (i.e., systolic blood pressure > 180 mm Hg, diastolic blood pressure > 95 mm Hg).
-
Prolonged rate corrected QT (QTc) interval >= 480 msec, calculated using the Fridericia method.
-
Patients with known severe or very severe chronic obstructive pulmonary disease (defined as forced expiratory volume in one second (FEV1) less than 30% or less than 50% of predicted), interstitial lung disease, or pulmonary fibrosis.
-
Female patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s).
-
Male patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s).
-
Patients with history of neutrophilic dermatosis (e.g. Sweet syndrome, pyoderma gangrenosum), relapsing polychondritis, polyarteritis nodosa and/or giant cell arteritis.
-
Patients with VEXAS syndrome (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic syndrome) or any other autoinflammatory disease.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Treatment (TAK-243)
Patients receive TAK-243 IV over 30 minutes on days 1, 4, 8, and 11 of each cycle. Cycles repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients undergo urine sample collection, bone marrow aspiration and bone marrow biopsy, MUGA and ECHO during screening and on study, and blood sample collection throughout the trial. |
Undergo bone marrow biopsy
其他名称:
Undergo ECHO
其他名称:
Undergo MUGA
其他名称:
Undergo bone marrow aspiration Undergo urine and blood sample collection
其他名称:
Given IV
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Recommended phase II dose (RP2D)
大体时间:At 21 days
|
RP2D will be identified based on maximum tolerated dose and additional safety data. Primary endpoint will be analyzed on the population assessable for safety of the phase 1 trial (escalation part). |
At 21 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of adverse events
大体时间:Up to 30 days after the last dose of TAK-243
|
Determined by clinical symptoms/signs, laboratory evaluation and imaging. Graded by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Will be recorded in terms of event type, severity, dates of beginning and end, reversibility and evolution. Data will be gathered in tables summarizing toxicities and side effects for each dose level and cycle. |
Up to 30 days after the last dose of TAK-243
|
|
Incidence of serious adverse events
大体时间:Up to 30 days after the last dose of TAK-243
|
Determined by clinical symptoms/signs, laboratory evaluation and imaging. Graded by CTCAE version 5.0. Will be recorded in terms of event type, severity, dates of beginning and end, reversibility and evolution. Data will be gathered in tables summarizing toxicities and side effects for each dose level and cycle. |
Up to 30 days after the last dose of TAK-243
|
|
Incidence of dose-limiting toxicities (DLTs)
大体时间:Within the first cycle (Up to 21 days)
|
DLT will be described in terms of number and incidence rates at each dose level. The number and percentage of patients who will have developed a DLT in each dose level will also be reported. |
Within the first cycle (Up to 21 days)
|
|
Rate of complete response (CR) in patients with acute myeloid leukemia (AML)
大体时间:Up to 1 year
|
As defined by European LeukemiaNet criteria. Categorical endpoints (e.g., response) will be reported in terms of counts by dose level. |
Up to 1 year
|
|
Rate of complete response with incomplete hematological recovery (CRi), in patients with AML
大体时间:Up to 1 year
|
As defined by European LeukemiaNet criteria. Categorical endpoints (e.g., response) will be reported in terms of counts by dose level. |
Up to 1 year
|
|
Rate of CR with partial hematological recovery (CRh) in patients with AML
大体时间:Up to 1 year
|
As defined by European LeukemiaNet criteria. Categorical endpoints (e.g., response) will be reported in terms of counts by dose level. |
Up to 1 year
|
|
Rate of partial response (PR) in patients with AML
大体时间:Up to 1 year
|
As defined by European LeukemiaNet criteria. Categorical endpoints (e.g., response) will be reported in terms of counts by dose level. |
Up to 1 year
|
|
Rate of morphologic leukemia-free state (MLFS) in patients with AML
大体时间:Up to 1 year
|
As defined by European LeukemiaNet criteria. Categorical endpoints (e.g., response) will be reported in terms of counts by dose level. |
Up to 1 year
|
|
Overall response rate (ORR) in patients with AML
大体时间:Up to 1 year
|
Will include CR, CRi plus CRh. Categorical endpoints (e.g., response) will be reported in terms of counts by dose level. |
Up to 1 year
|
|
Time to response in patients with AML
大体时间:From study treatment initiation (Cycle 1 Day 1) to achievement of CR, CRi or CRh, assessed up to
|
Categorical endpoints (e.g., response) will be reported in terms of counts by dose level. |
From study treatment initiation (Cycle 1 Day 1) to achievement of CR, CRi or CRh, assessed up to
|
|
Overall survival (OS) in patients with AML
大体时间:From study treatment initiation to death (of any cause) or last follow-up, assessed at 6 months and 1 year
|
OS rates will be reported. OS will be analyzed using the Kaplan-Meier method. The median survival rates will be reported with a 95% confidence interval. Median follow-up will be calculated using the reverse Kaplan-Meier method. |
From study treatment initiation to death (of any cause) or last follow-up, assessed at 6 months and 1 year
|
|
Relapse-free survival (RFS) in patients with AML
大体时间:From CR, CRi or CRh to the first occurrence of disease relapse, death (of any cause) or last follow-up, whichever occurs first, assessed at 6 months and 1 year
|
Will be analyzed using the Kaplan-Meier method. The median survival rates will be reported with a 95% confidence interval. Median follow-up will be calculated using the reverse Kaplan-Meier method. |
From CR, CRi or CRh to the first occurrence of disease relapse, death (of any cause) or last follow-up, whichever occurs first, assessed at 6 months and 1 year
|
|
Rate of CR in patients with myelodysplastic syndrome (MDS)
大体时间:Up to 1 year
|
Categorical endpoints (e.g., response) will be reported in terms of counts by dose level. |
Up to 1 year
|
|
Rate of CR equivalent in patients with MDS
大体时间:Up to 1 year
|
Categorical endpoints (e.g., response) will be reported in terms of counts by dose level. |
Up to 1 year
|
|
Rate of CR with limited count recovery (CRL) in patients with MDS
大体时间:Up to 1 year
|
Categorical endpoints (e.g., response) will be reported in terms of counts by dose level. |
Up to 1 year
|
|
Rate of CR with partial hematologic recovery (CRh) in patients with MDS
大体时间:Up to 1 year
|
Categorical endpoints (e.g., response) will be reported in terms of counts by dose level. |
Up to 1 year
|
|
Rate of marrow CR in patients with MDS
大体时间:Up to 1 year
|
Categorical endpoints (e.g., response) will be reported in terms of counts by dose level. |
Up to 1 year
|
|
Rate of PR in patients with MDS
大体时间:Up to 1 year
|
Categorical endpoints (e.g., response) will be reported in terms of counts by dose level. |
Up to 1 year
|
|
ORR in patients with MDS
大体时间:Up to 1 year
|
Defined by the revised International Working Group 2023 response criteria for higher-risk MDS. Categorical endpoints (e.g., response) will be reported in terms of counts by dose level. |
Up to 1 year
|
|
Time to response in patients with MDS
大体时间:From study treatment initiation (Cycle 1 Day 1) to achievement of CR, CRL or CRh, assessed up to 1 year
|
Categorical endpoints (e.g., response) will be reported in terms of counts by dose level. |
From study treatment initiation (Cycle 1 Day 1) to achievement of CR, CRL or CRh, assessed up to 1 year
|
|
OS in patients with MDS
大体时间:From study treatment initiation to death (of any cause) or last follow-up, assessed at 6 months and 1 year
|
OS rates will be reported. OS will be analyzed using the Kaplan-Meier method. The median survival rates will be reported with a 95% confidence interval. Median follow-up will be calculated using the reverse Kaplan-Meier method. |
From study treatment initiation to death (of any cause) or last follow-up, assessed at 6 months and 1 year
|
|
Progression-free survival (PFS) in patients with MDS
大体时间:From study treatment initiation to the first occurrence of progressive disease (PD), relapse from CR (or CR equivalent), death (of any cause), or last follow-up whichever occurs first, assessed at 6 months and 1 year
|
PFS rates will be reported. PFS will be analyzed using the Kaplan-Meier method. The median survival rates will be reported with a 95% confidence interval. Median follow-up will be calculated using the reverse Kaplan-Meier method. |
From study treatment initiation to the first occurrence of progressive disease (PD), relapse from CR (or CR equivalent), death (of any cause), or last follow-up whichever occurs first, assessed at 6 months and 1 year
|
|
Pharmacokinetic measurements
大体时间:Baseline up to 1 year
|
Expressed as area under the curve (AUC), half-life (t1/2), and maximum concentration (Cmax). |
Baseline up to 1 year
|
|
Demonstration of UBA1-TAK-243 engagement
大体时间:Baseline up to 1 year
|
Assayed by proprietary monoclonal antibody courtesy of Takeda, to determine target binding and inhibition. |
Baseline up to 1 year
|
|
Reductions of protein mono- and poly ubiquitylation
大体时间:Baseline up to 1 year
|
Measured by FK2 antibody. Used as a functional marker of target inhibition. |
Baseline up to 1 year
|
合作者和调查者
调查人员
- 首席研究员:Guillaume Richard-Carpentier、University Health Network Princess Margaret Cancer Center LAO
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- NCI-2019-00238
- UM1CA186644 (美国 NIH 拨款/合同)
- NCI-2019-00238 (注册表标识符:CTRP (Clinical Trial Reporting Program))
- 10237 (其他标识符:CTEP)
- 10237 (其他标识符:University Health Network Princess Margaret Cancer Center LAO)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.